Differential involvement of CD4+ cells in mediating skin graft rejection against different amounts of transgenic H-2K(b) antigen by unknown
BriefDefinitive Report
Differential Involvement of CD4+ Cells in Mediating
Skin Graft Rejection against Different Amounts of
Transgenic H-2Kb Antigen
By Minoru Kawai,* Yuichi Obata,# Noriyuki Hamasima,#
Toshitada Takahashi,$ Akiko Uenaka,$ Morito Monden,*
Takesada Mori,* Hiroshi Shiku,II and Eiichi Nakayamall
From the "Department ofSurgery, Osaka University Medical School, Osaka 530,
the #Department of Immunology, Aichi Cancer Center Research Institute, Nagoya 464;
the DDppartment of Tumor Immunology, Center for Adult Diseases, Osaka 537, and the
IlDepartment of Oncology, Nagasaki University School of Medicine, Nagasaki 852, Japan
Summary
Differential involvement of CD4* cells in mediating class I-disparate skin graft rejection was
investigated using quantitatively different Kb transgenic mice as donors under conditions in
which CD8+ cells were blocked in vivo by administration of anti-CD8 monoclonal antibody
(mAb). Tg.H-2Kb-1 and -2 are C3H transgenic mice with 14 and 4 copies, respectively, of the
H-2Kb gene. Cell surface expression of Kb antigen and the Kb antigenicity of skin for eliciting
graft rejection with homozygous and heterozygous transgenic mice were correlated with the
copy number. In vivo administration of anti-Lyt-2.1 (CD8) mAb markedly prolonged survival
of heterozygous and homozygous C3H Tg.H-2Kb-2 skin grafted onto C3H mice, but prolonged
survival of heterozygous Tg.H-2Kb-1 skin grafts much less and did not prolong survival of
homozygous Tg.H-2Kb-1 grafts. Administration of anti-L3T4 (CD4) mAb alone did not have
any effect on skin graft rejection. Administration of anti-L3T4 (CD4) mAb with anti-Lyt-2.1
(CD8) mAb blocked rejection in all combinations. These findings indicate that a quantitative
difference of class I antigen caused differential activation of CD4+ cells under conditions in
which CD8+ cells were blocked.
F
rom studies on the immune responses of C57BL/6 (B6)
mice to grafts from B6.C-H-2bmt (bm1) and B6.C-
H-2b-'2 (bm12) mutant mice (1), CD4' cells are now thought
to mediate rejection of MHC class II antigen, and CD8+
cells are thought to mediate rejection of MHC class I an-
tigen. But evidence is accumulating that the ability to reject
an allograft is not a unique feature of a given T cell pheno-
type (2) . For example, CD4+ cells have been shown to
mediate skin graft rejection of allogeneic class I antigen (3,
4) and minor H antigen, the recognition of which was shown
to be restricted to class I (2) . Moreover, the presence of
CD4+ CTL reactive against MHC class I antigen has re-
cently been demonstrated (5-7).
We showed previously that CD4+ cells were activated im-
mediately for mediating skin graftrejection in some class 1-dis-
parate combinations, when CD8+ cells were blocked in
vivo, but were activated less efficiently in other combinations,
and that this activation was correlated with antibody produc-
tion against donor MHC class I antigen (4). Thus, CD4+
cells were differentially activated in response to allelic MHC
classI antigens by recognizing a differencebetween the donor
and recipient in polymorphic determinants on class I mole-
cules (8).
In this study, using transgenic C3H/He (C3H) mice into
which different numbers of Kb genes were introduced, we
found that activation of CD4+ cells for mediating skin graft
rejection is also determined by the quantity of MHC class
I antigen.
Materials and Methods
Mice.
￿
C57BL/6 (B6) mice were obtained from Shizuoka Labo-
ratory Animal Center (Shizuoka, Japan). C3H/He (C3H) mice
were purchased from Charles River Breeding Laboratories (Hino,
Japan).
Transgenic Mice.
￿
Transgenic strains carrying the H-2K1 genes,
Tg.H-2K'-1 and -2, were described previously (9). Briefly, the
DNA suspension was injected into the male pronuclei offertilized
eggs obtained from C3H mice by the method of Gordon et al.
(10). The copy numbers of transgeneswere determined by Southern
blot analysis with a DNA preparation from the tail to be seven
in Tg.H-2K'-1 and two in Tg.H-2K'-2 per haploid.
mAbs.
￿
Anti-L3T4 (CD4) mAb, a rat antibody of the y2bK Ig
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F . Fitch, University of Chicago (Chicago, IL) (11) . Anti-Lyt-2.1
(CD8) mAb has been described previously (12) . These antibodies
were used in the form of ascites from hybridoma-bearing mice.
Radioiodination .
￿
Cells were radioiodinated with Na'"I (New
England Nuclear, Boston, MA) by Iodo-gen (Pierce Chemical Co .,
Rockford, IL) (13) . Cells were then treated with 3,3'-dithio-
bissulfosuccinimidylpropionate (DTSSP) (Pierce Chemical Co .)
(20 gg/ml) for 20 min at 4°C for crosslinking . Cell lysates were
prepared by incubating labeled cells in lysis buffer consisting of
1% NP-40, 5 x 10 -5 M PMSF, and 0.05 M iodoacetamide in
0 .1 M Tris .
Immunoprecipitation.
￿
Aliquots of radiolabeled cell extracts were
incubated with mAb for 1 h at room temperature, and 100,ul of
20% Pansorbin (Calbiochem-Behring Corp ., La Jolla, CA) was
added to induce immunoprecipitation . Bound antigen was eluted
by heating and was analyzed by SDS-PAGE (14) .
Cytofluorometry Analysis.
￿
Cells (106) were incubated with bi-
otinylated NU5-2 (anti-H-2K6) mAb, and then with FITC-
conjugated avidin . For double staining, FITC-conjugated anti-L3T4
(CD4)mAb (cloneGK1 .5) and PE-conjugated rat anti-Lyt-2 (CD8)
mAb (clone 53-6.7) (Becton Dickinson& Co., Sunnyvale, CA) were
used . Then the cells were washed, suspended in PBS, and analyzed
in an Epics-C apparatus (Coulter Electronics Inc ., Hialeah, FL).
Skin Grafting.
￿
Full-thickness skin was grafted, and rejection
was defined as 50% necrosis.
Antibody Administration.
￿
Mice received injections of0 .2 ml of
antibodies (ascites), diluted 1:8 with MEM, on days 0, 4, and 14,
and then at weekly intervals until rejection .
Results
Expression of H-2Kb Antigen in Transgenic Tg.H-2Kb-1 and
-2 Mice. The H-21(b gene was introduced into fertilized
eggs ofC3H mice, and two strains of transgenic mice, Tg.H-
2Kb-1 and -2, were established (9) . Southern blot analysis
showed that the Tg.H-2Kb-1 and -2 mice contained seven
and two copies per haploid, respectively, integrated into a
single chromosomal site (9) . Expression of H-21(b antigen
on lymphoid cells from these mice was investigated by
cytofluorometry using NU5-2mAb, and compared with that
onlymphoid cells fromB6 mice (Fig. 1, a-e). The peak fluores-
cence modes ofhomozygous and heterozygous Tg.H-2Kb-1
were within ranges of1.48-2.01 and 1.02-1.07 (n = 3), respec-
tively, while those of homozygous and heterozygous Tg.H-
2Kb-2 were within ranges of 0.89-0.96 and 0.60-0.72 (n =
3), respectively . In immunoprecipitation tests, NU5-2 mAb
reacted with 45-kD (class I H chain) and 57-kD ((02micro-
globulin-associated H chain) molecules on crosslinking in the
lysates ofsurface-iodinated lymph node cells from B6, Tg.H-
2Kb-1 and -2 mice, but not from C3H mice (Fig . 1 f) .
Survival of Skin from Tg.H-2Kb-1 and -2 Mice Grafted onto
C3HMice. The effect of the quantity of donor H-2Kb an-
tigen on rejection was investigated by skin grafting with com-
binations of Tg.H-2Kb-1 or -2 mice as donors, and C3H
mice as recipients. The mean graft survivals (MGS) of skins
from homozygous and heterozygous Tg.H-2Kb-1 mice
grafted onto C3H mice were 13.9 ± 0.8 and 15.5 ± 1.2
d, respectively (Table 1) . The MGS of grafts from homozy-
gous and heterozygous C3H Tg.H-2Kb-2 mice grafted onto
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Figure 1 .
￿
Expression of transgenic Kb antigen examined by cytofluor-
ometry analysis (a-e) and immunoprecipitation Y) . Lymph node cells from
homozygous (a) and heterozygous (b) Tg.H-2Kb-1, and homozygous (c)
and heterozygous (d) Tg.H-2Kb-2 mice were incubated with biotinylated
NU5-2 (anti-Kb) mAb and then with FITC conjugated avidin . Dotted
line represents control B6 lymph node cells. (e) Normal C3H lymph node
cells . Inf, molecules reactive with NU5-2 (anti-Kb)mAb were crosslinked
by DTSSP and immunoprecipitated from NP-40 1ysates of surface-iodinated
lymph node cells from C3H (lane 1), B6 (lane 1), Tg.H-2Kb-1 (lane 3),
and -2 (lane 4) mice .
C3H mice were 17 .9 ± 1.2 and 19.8 ± 1.6 d, respectively.
No rejection of skin grafts was observed with reciprocal com-
binations between Tg.H-2Kb-1 and -2 mice.
Effect ofIn Vivo Administration ofAnti-L3T4 (CD4) and/or
Anti-Lyt-2.1 (CD8) mAb on Transgenic H-2K6-disparate Skin
Graft Rejection . To investigate the responses of CD4+ cells
to quantitatively different amounts of transgenic H-2 Kb an-
tigen, we examined the effect of in vivo administration of
anti-L3T4 (CD4) and/or anti-Lyt-2.1 (CD8) mAb on skin
graft rejection . Antibodies were injected on days 0, 4, and
14, and then at weekly intervals until rejection. Cytofluoro-
metric analysis showed that CD4+ and CD8+ cells were
selectively depleted for at least 50 d after in vivo treatment
ofC3H mice with anti-L3T4 (CD4) and anti-Lyt-2.1 (CD8)
mAb, respectively (Fig . 2) . Blocking of the functions of
CD4+ cells and CD8+ cells in vivo by mAb treatment was
examined by monitoring skin graft rejection in combinations
of H-2b mutant strains and B6 .
A single injection of anti-L3T4 (CD4) mAb prolonged
survival in B6 mice of bm12 skin (MGS, 32.8 ± 12.1 d
[p < 0.05] ; MGS in MEM-treated mice, 12.8 ± 1.2 d), but
not bm1 skin (MGS, 12.0 ± 1.0 d; MGS in MEM-treated
mice, 15 .0 ± 0.9 d) . On the other hand, anti-Lyt-2.1 (CD8)
mAb prolonged the survival in B6 mice ofbm1 skin (28.4)
± 9.9 d [p < 0.05]), but not bm12 skin (12.2 ± 0.8 d) .Administration of anti-L3T4 (CD4) mAb did not alterthe
survival of skin from either homozygousor heterozygous C3H
Tg.H-2Kb-1 or -2 mice grafted onto C3H mice (Fig. 3).
Administration of anti-Lyt-2.1 (CD8) mAb markedly pro-
longed the survival ofgrafts from heterozygous and homozy-
gous Tg.H-2Kb-2 mice slightly, but not significantly, pro-
longed the survival of skin from heterozygous Tg.H-2Kb-1,
but did not prolong survival of skin from homozygous Tg.
H-2Kb-1. Administration of anti-L3T4 (CD4) mAb in ad-
dition to anti-Lyt-2.1 (CD8) mAb blocked rejection in all
combinations.
Discussion
In this study, using transgenic mice, we showed that graft
survival was determined by the quantity of donor Kb an-
tigen. The expressions of Kb antigen in homozygous and
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Figure 2. Three-dimensional
cytofluorometric analysisoflymph
node cells from C3H mice 21 d
afterinjections ofanti-L3T4 (CD4)
mAb (b) or anti-Lyt-2.1 (CD8)
mAb (c) on days 0, 4, and 14. (a)
Untreated.
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heterozygous Tg.H-2Kb-1 and -2 mice depended on the
number of copies introduced. A correlation of the quantity
of transgenic Kb antigen expressed on the cell surface with
in vivo antigenicity was demonstrated in skin graft rejection.
The MGS ofskin from homozygous and heterozygous Tg.H-
2Kb-1, and homozygous and heterozygous Tg.H-2Kb-2,
grafted onto OH mice increased in this order in parallel with
a decrease in the quantity of Kb antigen expressed. These
results are consistent with previous findings that an increase
in the MHC class I product appears to have a direct effect
on T cell recognition and enhances susceptibility to lysis by
cytotoxic T cells (15).
We also demonstrated that the mode of involvement of
CD4+ cells in mediating rejection was determined by the
quantity of donor Kb antigen. Prolongation of graft survival
by in vivo administration of anti-CD8 mAb was greatest with
heterozygous Tg.H-2Kb-2 skin, and was not observed with
homozygous Tg.H-2Kb-1 skin grafted onto C3H mice. Ad-
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Effects ofin vivo administration ofMEM(control)("), anti-
L3T4 (CD4) mAb (A), anti-Lyt-2.1 (CD8) mAb (0), or both (O) on
survival of skin from homozygous (a) andheterozygous (b) Tg.H-2Kb-1,
homozygous (c) and heterozygous (d) Tg. H-2Kb-2 grafted onto C3H
mice. No rejection was observed by a 200-d observation period with all
five grafts examined.
Table 1. Elect of Transgenic K6 Antigen
Donor
Quantity on Skin Graft Survival
Recipient Skin graft survival
d
Tg.H-2Kb-1 (homozygous) C3H 13.9 ± 0.8"` (n = 10)
Tg.H-2Kb-1 (heterozygous) C3H 15 .5 ± 1.2 (n = 10)
Tg.H-2Kb-2 (homozygous) C3H 17 .9 ± 1.2 (n = 10)
Tg.H-2Kb-2 (heterozygous) C3H 19.8 ± 1.6 (n = 9)
Tg.H-2Kb-1 (homozygous) Tg.H-2Kb-2 (homozygous) >200 x 5
Tg.H-2Kb-2 (homozygous) Tg.H-2Kb-1 (homozygous) >200 x 5
" Mean ± SD.ministration of anti-CD4 mAb with anti-CD8 mAbblocked
rejection in allcombinations tested, confirming the involve-
ment of CD4+ cells in rejection when CD8+ cells were
blocked. We previously demonstrated that in some strain com-
binations with a class I antigen difference, CD4+ cells were
capableofmediatingimmediate rejection of skin grafts when
CD8+ cells hadbeen blocked by administration of anti-CD8
mAb, whereas, in other strain combinations, CD4+ cells
were much less effective (4). Thus, notonly aqualitative differ-
ence based on allelic polymorphism, but also a quantitative
difference of class I antigen caused differential activation of
CD4+ cells when CD8+ cells were blocked.
The response of CD4+ cells is generally thought to be re-
stricted to class II antigen both in vitro andin vivo (1). How-
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